3D InSight™ Combinatorial Drug Testing Service | InSphero

Reveal potential combinatorial effects of drug pairs in more relevant 3D tumor models

Test your drug of interest in combination with other therapeutics to identify pairs with synergistic, additive, or antagonistic effects. We determine potency (EC50), efficacy (maximum response) and growth kinetics of 2 compounds alone and in combination, using size and ATP (viability) endpoints over a 10 day dosing period.

Service Protocol

  • Determine EC20 and EC50 using ATP and size after 5-day exposure (test drug & TAX, DOX, STA)
  • Perform relapse assay comparing pulsed dosing (day 0 only) at EC20 and EC50 to repeat dosing (day 0, 3, 7) at maximum concentration over time
  • Classify relapse potential

Characterization Data

Slide Reveal synergistic combinatorial growth inhibition. Simultaneous treatment of MX-1 (breast)/NIH3T3 tumor/fibroblast co-culture spheroids with Gemcitabine and Docetaxel reveals more potent combinatorial growth inhibition compared to treatment with either compound alone. Slide Utilize bright-field assessment for continuous, non-disruptive assessment of tumor growth. Simultaneous treatment of two test compounds as pairwise combination in melanoma primary cell derived microtissues.

Service at a Glance

Service Report includes

  • ATP-based dose-response curve
  • Growth kinetics over time
  • Potency (EC50), efficacy (max response) and combinatorial analysis
Catalog # Description
SP-01-042-02 3D InSight™ Combinatorial Drug Testing Service (2 compounds, 1 control, 1 model)

Request Additional Resources

Brochure: Oncology Services

Request

Poster: 3D InSight™ Oncology Drug Discovery Platform

Request

Brochure: Immuno-oncology services

Request

Find out how you can screen new cancer drugs more efficiently

with services using our advanced 3D tumor models.

Get Started